Search results for: 'clinical trials and obesity'
- Did you mean
- clinical trials ad obesity
- Related search terms
- AND 6153=5227-- cSlQ
- clinical communications market research
- clinical environment market size ® invest 2025
- clinical environment market size ® invest 2030
- clinical environment market size ® invest 2020
-
12 Jun 2024  |  Global  |  Market Research
Innovative AI-enabled Clinical Trial Companies: Strategic Profiling and Growth Opportunities
The Integration of Real-world Insights into Trial Management is Propelling AI Adoption in Clinical Trials
As global clinical pipelines witness a surge in complex novel therapies, there is a general inclination toward improving trial design through adaptive trial designs with technology-enabled solutions for planning and execution. Artificial intelligence (AI) is gaining large-scale recognition in terms of supporting decentralized trial designs and allo...
$2,450.00
Special Price $1,837.50 save 25 %
-
06 Aug 2026  |  Global  |  Technology Research
Decentralized Clinical Trials Powered by Blockchain and Digital Twins
Clinical trials are evolving into AI-enabled, connected ecosystems that improve efficiency, transparency, and patient accessibility
This report examines how decentralized clinical trials (DCTs), enabled by blockchain, digital twins, and artificial intelligence, are reshaping global clinical research. It traces the shift from site-centric to patient-centric models and quantifies the growing scale, globalization, and complexity of clinical trials that make decentralization necess...
$4,950.00 -
12 Jan 2026  |  Global  |  Frost Radar
Frost Radar™: Artificial Intelligence-Enabled Clinical Trials, 2026
A Benchmarking System to Spark Companies to Action - Innovation That Fuels New Deal Flow and Growth Pipelines
Artificial intelligence (AI) has been revolutionizing the technology-enabled drug discovery and development landscape. In clinical research, AI has been gaining traction across site selection, trial design and protocol optimization, and patient recruitment and management. Because data is the core discipline of drug development, electronic medical r...
$4,950.00 -
08 Jul 2026  |  Global  |  Technology Research
Precision Obesity Management: AI-Guided Metabolic Modulation
Emerging Innovations Driving Personalized and Effective Obesity Solutions
The report explores the transformation of obesity care from generalized BMI-based treatment to AI-enabled precision metabolic management. The study highlights how obesity is increasingly recognized as a heterogeneous, multi-pathway disease influenced by genetic, neurobehavioral, metabolic, and environmental factors, requiring personalized therapeut...
$4,950.00 -
28 Nov 2023  |  Global  |  Technology Research
Growth Opportunities in Obesity Drugs and Delivery Platforms
GLP-1-based Drugs, Along With Injector and Nanomaterial Delivery Platforms, Drive Transformational Industry Growth
The increasing disposable incomes in developing countries have contributed to a sedentary lifestyle worldwide. The advent of food delivery apps has also increased accessibility to various culinary delights. These factors have contributed mainly to obesity and other lifestyle diseases. People with a body mass index (BMI) of more than or equal to...
$4,950.00
Special Price $3,712.50 save 25 %
-
14 Jun 2024  |  Global  |  Market Research
Growth Opportunities in Global Diabetes and Obesity Therapeutics, 2024 2028
GLP-1 RA Drug Class, Combination Therapies, and Digital Convergence for Affordable Disease Management Drive Growth
Globally, diagnosis of metabolic diseases such as type 2 diabetes and obesity have increased. Since the COVID-19 pandemic, the global prevalence of obesity has worsened. Obesity is considered a main precursor of diabetes and contributes an estimated 80% to 85% toward the risk of type 2 diabetes. As a result, the financial burden associated with hea...
$4,950.00
Special Price $3,712.50 save 25 %
-
06 Feb 2018  |  Global  |  Market Research
Growth Opportunities in Clinical Trial Data Management and eClinical Solutions Market, Forecast to 2020
Digitization Presents Opportunities for Unified Cloud-based Platform Solutions to Optimize Clinical Trial Workflows
The global clinical trial IT market is expected to grow from $2.63 billion in 2016 to $4.29 billion in 2020 at a compound annual growth rate (CAGR) of more than 13.0%. North America will continue to hold the largest market share (by revenue) in 2017, followed by Europe. Increasing clinical trial activities in the emerging Asia-Pacific markets and r...
$4,950.00
Special Price $3,712.50 save 25 %
-
02 Mar 2017  |  Global  |  Technology Research
Biomarkers Enabling Diabetes and Obesity Management
Novel Biomarker Research is Likely to Transform the Future of Obesity and Diabetes Management
Obesity and diabetes are areas of growing concern across both, developed and developing countries. The rising geriatric population is likely to contribute to an increased prevalence of obesity and diabetes across the global landscape. Biomarker research is likely to facilitate the emergence of novel tools that may be useful for enhanced management ...
$4,950.00
Special Price $3,712.50 save 25 %
-
18 Apr 2024  |  Global  |  Market Outlook
Global Clinical Diagnostics Outlook, 2024
Driven by Digital Services and Automation, the Molecular Diagnostics and POCT Sectors Rebound after the COVID-19 Pandemic
With the end of the COVID-19 pandemic, healthcare providers have been directing most of their capabilities toward preventive healthcare and precision medicine, as the clinical diagnostics industry continues its transition from a centralized to a decentralized testing model. Globally, 2024 is set to be a profitable year for the industry, which will ...
$4,950.00
Special Price $3,712.50 save 25 %
-
22 Sep 2025  |  Global  |  Technology Research
Growth Opportunities in Weight Management Technologies
Emerging Innovations Driving Personalized and Effective Obesity Solutions
This study focuses on emerging pharmacological and non-pharmacological strategies in the treatment of obesity, as well as evolving new paradigms for the future. It describes the contribution of incretin-based therapies, particularly GLP-1 receptor agonists and their multi-agonist counterparts, which provide robust effects on weight loss and metabol...
$4,950.00